An interventional study of CAPSULaser and capsulotomy in Intumescent Cataract, sponsored by Zagazig University. Completed at 1 site in Saudi Arabia. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Zagazig University · Not applicable, Interventional, and Treatment
evaluating the use of selective laser in doing capsulotomy in intumescent cataract
Evaluating the safety and advantages of using selective laser capsulotomy for capsulorhexis creation in intumescent cataract
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 24 is below the median of 80 across 1,155 interventional studies indexed under Cataract.
Browse Cataract studies →Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
CAPSULaser
Procedure: CAPSULaser · Device: capsulotomy
doing capsulotomy using CAPSULaser
capsulorhexis using CAPSULaser
To measure the actual size compared to result size as measured by slit lamp in mm
To measure the actual size compared to result size as measured by slit lamp
Time frame: 3 months
Incidence and number of extended capsulorhexis to the total number of cases
Incidence and number of extended capsulorhexis
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zagazig University